The shadow of generic challenges has consistently loomed around copyright’s blockbuster drug, escort Sildenafil, triggering questions about the outlook of connected drug ventures. While initial periods saw substantial returns, the patent end has created the way for cheaper copies, potentially diminishing revenue and presenting a significant risk